TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
22 hedge funds and large institutions have $30.4M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
4% less funds holding
Funds holding: 23 → 22 (-1)
27% less capital invested
Capital invested by funds: $41.9M → $30.4M (-$11.5M)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$282K |
| 2 |
CAM
ClariVest Asset Management
San Diego,
California
|
+$49.8K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$35.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14.2K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$11.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$626K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$305K |
| 3 |
VAM
Visium Asset Management
New York
|
-$259K |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$121K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$96K |
TCON Hedge Fund Activity: Q1 2016 in Review
22 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q1 2016, worth a combined $30.4M — down 27% from $41.9M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of TCON and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $282K. The largest seller was Deerfield Management, cutting an estimated $626K.
- 22 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q1 2016, down from 23 in Q4 2015.
- Funds reported $30.4M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q1 2016, down 27% quarter-over-quarter.
- 2 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q1 2016 and 3 closed out, a net change of -1 holder.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q1 2016 was Vanguard Group, an estimated $282K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q1 2016 was Deerfield Management, an estimated $626K sold.
Based on aggregated 13F filings for Q1 2016.